Avadel pharmaceuticals announces ongoing fda review of nda for ft218 for patients with narcolepsy

Dublin, ireland, oct. 15, 2021 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a company focused on transforming medicines to transform lives, announced today that the u.s. food and drug administration (fda) notified the company that the review of the new drug application (nda) for ft218 is still ongoing, and action will likely not be taken in october. the fda informed the company that there are no information requests at this time and a new target action date will be provided as soon as possible.
AVDL Ratings Summary
AVDL Quant Ranking